Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: A nationwide population-based cohort study

Cancer Medicine

Volumn 5, Issue 4, 2016, Pages 640-648

  Fleischer, Tom ^a   Chang, Tung Ti ^a,b   Chiang, Jen Huai ^a,b,c   Chang, Ching Mao ^d,e   Hsieh, Ching Yun ^b   Yen, Hung Rong ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

CML; NHIRD; Chinese herbal medicine; Leukemia; Taiwan

Indexed keywords

BUSULFAN; DASATINIB; GUI PI TANG; HERBACEOUS AGENT; HYDROXYUREA; IMATINIB; INTERFERON; JI SHENG SHEN QI WAN; JIA WEI XIAO YAO SAN; LIU WEI DI HUANG WAN; NILOTINIB; PING WEI SAN; QI JU DI HUANG WAN; SHAO YAO GAN CAO TANG; SHEN LING BAI ZHU SAN; SHENG MAI YIN; UNCLASSIFIED DRUG; XIN YI QING FEI TANG;

ADULT; AGE; AMOMUM; AMOMUM VILLOSUM; ARTICLE; ASTRAGALUS MEMBRANACEUS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORYDALIS; CORYDALIS YANHUSUO; DIOSCOREA OPPOSITIFOLIA; DRUG USE; FEMALE; GENDER; GLYCYRRHIZA GLABRA; HEDYOTIS; HEDYOTIS DIFFUSA; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; OPHIOPOGON JAPONICUS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; REHMANNIA GLUTINOSA; SALVIA MILTIORRHIZA; SPATHOLOBUS SUBERECTUS; URBANIZATION; ADJUVANT CHEMOTHERAPY; FACTUAL DATABASE; HEALTH SURVEY; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; TAIWAN; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; TAIWAN; TREATMENT OUTCOME;

EID: 84981763954     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.627     Document Type: Article

References (23)

1. Druker, B. J., F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, et al. 2006. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N. Engl. J. Med. 355:2408-2417.
2. Cortes, J. E., D. W. Kim, J. Pinilla-Ibarz, P. le Coutre, R. Paquette, C. Chuah, et al. 2013. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369:1783-1796.
3. Lucas, C. M., L. Wang, G. M. Austin, K. Knight, S. J. Watmough, K. H. Shwe, et al. 2008. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22:1963-1966.
4. Deininger, M., S. G. O'Brien, F. Guilhot, J. M. Goldman, A. Hochhaus, T. P. Hughes, et al. 2009. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Ann.Meet. Abstr. 114:1126.
5. Chang, C. S., Y. H. Yang, C. N. Hsu, and M. T. Lin . 2012. Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. BMC Health Serv. Res. 12:359.
6. Kantarjian, H., S. O'Brien, E. Jabbour, G. Garcia-Manero, A. Quintas-Cardama, J. Shan, et al. 2012. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienced. Blood 119:1981-1987.
7. Jiang, H., L. P. Xu, D. H. Liu, K. Y. Liu, S. S. Chen, B. Jiang, et al. 2014. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant. 49:1146-1154.
8. Pavlů J, S. R., G. JM, and A. JF . 2011. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 117:755-763.
9. Yang, G., X. Li, X. Li, L. Wang, J. Li, X. Song, et al. 2012. Traditional chinese medicine in cancer care: a review of case series published in the chinese literature. Evid. Based Complement. Alternat. Med. 2012:751046.
10. Chen, F. P., T. J. Chen, Y. Y. Kung, Y. C. Chen, L. F. Chou, F. J. Chen, et al. 2007. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv. Res. 7:26.
11. Office of Information Services, Executive Yuan. 2012. The Republc of China (Taiwan) - Yearbook. Executive Yuan, Taiwan. Available at: http://www.ey.gov.tw/2012yearbook/index.html(Accessed 11 January 2015).
12. Breccia, M., L. Luciano, R. Latagliata, F. Castagnetti, D. Ferrero, F. Cavazzini, et al. 2014. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk. Res. 38:1173-1176.
13. Gugliotta, G., F. Castagnetti, M. Fogli, M. Cavo, M. Baccarani, and G. Rosti . 2013. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev. Hematol. 6:563-574.
14. Huang, X., J. Cortes, and H. Kantarjian . 2012. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123-3127.
15. D'Arena, G., L. Laurenti, M. Coscia, A. Cortelezzi, A. Chiarenza, G. Pozzato, et al. 2014. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk. Lymphoma 55:841-847.
16. Hensel, M., M. Zoz, and A. D. Ho . 2009. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support. Care Cancer 17:47-52.
17. DOH. Enabling Excellence: Autonomy and Accountability for Health and Social Care Staff. In: UK Department of Health, ed. Avaliable at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216580/dh_124374.pdf, 2011:29 (Accessed 11 January 2015).
18. CMBA. Chinese Medicine Registrant Data. 2013. Avaliable at: http://www.chinesemedicineboard.gov.au/About/Statistics.aspx Chinese Medicine Board of Australia (Accessed 11 January 2015).
19. Clarke, T. C., L. I. Black, B. J. Stussman, P. M. Barnes, and R. L. Nahin . 2015. Trends in the use of complementary health approaches among adults: United States, 2002-2012 Vol. 79. National Center for Health Statistics, National health statistics reports.
20. Jootar, S. 2012. CML treatment in Asia-Pacific region. Hematology (Amsterdam, Netherlands) 17(Suppl 1):S72-S74.
21. Chen, L. C., T. C. Chen, Y. B. Huang, and C. S. Chang . 2014. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. Int. J. Clin. Pharm. 36:120-127.
22. Chen, T.-C., L.-C. Chen, Y.-B. Huang, and C.-S. Chang . 2014. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int. J. Clin. Pharm. 36:172-181.
23. Gospodarowicz, M. K., B. O'Sullivan, and L. H. Sobin . 2006. Prognostic Factors in Cancer, 3rd ed. Wiley-Blakwell, United States.